In the News

Dr. Todd Levine Talks With Medical World News About the Potential of the Syn-One Test™ to Impact Patients’ Care

By December 22, 2020 December 23rd, 2020 No Comments

Dr. Todd Levine Talks With Medical World News About the Potential of the Syn-One Test™ to Impact Patients’ Care 

Todd Levine, MD, Co-Founder and Chief Medical Officer of CND Life Sciences was recently interviewed on Medical World News about the development of the Syn-One Test, how it can lead to better clinical decision making, and its potential to significantly impact the lives of patients with Parkinson’s disease, dementia with Lewy bodies, pure autonomic failure, and multiple system atrophy. He also discusses a new clinical trial that aims to further refine the diagnostic information the Syn-One Test can provide about these diseases, collectively known as synucleinopathies.  

WATCH THE INTERVIEW
CND Life Sciences

CND Life Sciences

CND Life Sciences is the creator of the Syn-One Test™, the world’s first commercially available test to visualize abnormal, phosphorylated alpha-synuclein in cutaneous nerve fibers. The test is an objective, evidence-based diagnostic tool to aid in the diagnosis of Parkinson’s disease, dementia with Lewy bodies, multiple system atrophy, pure autonomic failure, or REM sleep behavior disorder.